E. Hersh

1.1k total citations
38 papers, 816 citations indexed

About

E. Hersh is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, E. Hersh has authored 38 papers receiving a total of 816 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 13 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in E. Hersh's work include Monoclonal and Polyclonal Antibodies Research (6 papers), Immune Cell Function and Interaction (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). E. Hersh is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), Immune Cell Function and Interaction (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). E. Hersh collaborates with scholars based in United States and Japan. E. Hersh's co-authors include M Keating, John T. Manning, Douglas F. Lake, Edward F. Schnipper, Yasuhiko Masuho, Gutterman Ju, Loretta M. Itri, James M. Reuben, T. Kawamura and W M Mitchell and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

E. Hersh

38 papers receiving 774 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Hersh United States 14 394 229 191 178 143 38 816
J J Gibbons United States 13 220 0.6× 250 1.1× 445 2.3× 55 0.3× 37 0.3× 24 987
Thomas Coyle United States 18 243 0.6× 132 0.6× 308 1.6× 50 0.3× 287 2.0× 34 1.1k
Yuya Nagai Japan 11 433 1.1× 226 1.0× 252 1.3× 60 0.3× 43 0.3× 43 853
Marina Panozzo Italy 19 349 0.9× 220 1.0× 204 1.1× 281 1.6× 17 0.1× 44 888
Martina Anzaghe Germany 9 412 1.0× 221 1.0× 270 1.4× 72 0.4× 53 0.4× 16 1.1k
Eiji Shinya Japan 16 455 1.2× 290 1.3× 203 1.1× 86 0.5× 32 0.2× 24 808
Martin Salden Netherlands 18 307 0.8× 90 0.4× 407 2.1× 30 0.2× 111 0.8× 38 1.2k
María Fernanda Pascutti Netherlands 18 374 0.9× 132 0.6× 122 0.6× 98 0.6× 128 0.9× 36 775
Vicky M.-H. Sung United States 12 302 0.8× 204 0.9× 300 1.6× 86 0.5× 160 1.1× 14 1.6k
Gianna Fiorucci Italy 22 522 1.3× 256 1.1× 590 3.1× 253 1.4× 45 0.3× 48 1.3k

Countries citing papers authored by E. Hersh

Since Specialization
Citations

This map shows the geographic impact of E. Hersh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Hersh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Hersh more than expected).

Fields of papers citing papers by E. Hersh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Hersh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Hersh. The network helps show where E. Hersh may publish in the future.

Co-authorship network of co-authors of E. Hersh

This figure shows the co-authorship network connecting the top 25 collaborators of E. Hersh. A scholar is included among the top collaborators of E. Hersh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Hersh. E. Hersh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zalupski, Mark M., Paul Conkling, F. Warren Nugent, et al.. (2010). A phase II randomized double blind multicenter trial of gemcitabine (Gem) plus imexon (IMX) versus Gem plus placebo (P) in patients with chemotherapy-naïve pancreatic adenocarcinoma (PC).. Journal of Clinical Oncology. 28(15_suppl). 4076–4076. 5 indexed citations
3.
Hamid, Omid, W J Urba, Michael Yellin, et al.. (2007). 7005 ORAL Ipilimumab (MDX-010) in patients with stage III/IV melanoma: kinetics and duration of response. European Journal of Cancer Supplements. 5(4). 397–397. 5 indexed citations
4.
Weber, Jeffrey S., E. Hersh, Michael Yellin, et al.. (2007). 7003 ORAL Ipilimumab (MDX-010) in patients with unresectable stage III or IV malignant melanoma: efficacy and safety data from a phase I trial. European Journal of Cancer Supplements. 5(4). 396–396. 1 indexed citations
5.
Hersh, E., et al.. (2006). Phase II trial of ABI-007 (Abraxane) in previously treated and chemotherapy na??ve patients with metastatic melanoma. Melanoma Research. 16(Supplement 1). S78–S78. 4 indexed citations
6.
O’Day, Steven, Michael B. Atkins, Jeffrey S. Weber, et al.. (2005). A phase II multi-center trial of maintenance biotherapy (MBT) after induction concurrent biochemotherapy (BCT) for patients (Pts) with metastatic melanoma (MM). Journal of Clinical Oncology. 23(16_suppl). 7503–7503. 7 indexed citations
7.
Dragovich, Tomislav, David S. Mendelson, Michael S. Gordon, et al.. (2005). Phase I trial of imexon (IMX) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3153–3153. 2 indexed citations
8.
Rinehart, J. J., Kim Margolin, Pierre L. Triozzi, et al.. (1995). Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.. PubMed. 1(10). 1139–44. 3 indexed citations
9.
Salmon, S. E. & E. Hersh. (1994). Sensitivity of Multiple Myeloma to Imexon in the Human Tumor Cloning Assay. JNCI Journal of the National Cancer Institute. 86(3). 228–230. 18 indexed citations
10.
Pincus, Seth H., Robert L. Cole, E. Hersh, et al.. (1991). In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. The Journal of Immunology. 146(12). 4315–4324. 44 indexed citations
11.
Hersh, E. & Thomas P. Miller. (1988). Malignant Lymphomas in Patients with Human Immunodeficiency Virus Infection. Recent results in cancer research. 112. 54–62. 5 indexed citations
12.
Hersh, E., et al.. (1988). Immunological Characteristics and Potential Approaches to Immunotherapy of HIV Infection. Recent results in cancer research. 112. 17–26. 1 indexed citations
13.
Hersh, E., John T. Manning, M Keating, et al.. (1986). Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood. 68(2). 493–497. 29 indexed citations
14.
Murray, James L., Marc K. Rosenblum, L. Lamki, et al.. (1985). Imaging findings and pharmacokinetics of 111-indium ZME-018 monoclonal antibody (MoAb) in malignant melanoma. OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information). 64(6). 385–390. 1 indexed citations
15.
Sun, Yuhui, et al.. (1983). Preliminary observations on the effects of the Chinese medicinal herbs Astragalus membranaceus and Ligustrum lucidum on lymphocyte blastogenic responses.. PubMed. 2(3). 227–37. 35 indexed citations
16.
Murphy, S. & E. Hersh. (1978). Immunotherapy of leukemia and lymphoma.. PubMed. 15(2). 181–203. 15 indexed citations
17.
Thompson, W. J., et al.. (1977). Nongenetic regulation of a specific form of lymphocyte cyclic amp phospho di esterase. Federation Proceedings. 36(3). 283. 1 indexed citations
18.
Hersh, E., et al.. (1973). Local and systemic immunologic effects of perfusion therapy for malignant melanoma.. PubMed. 137(3). 461–4. 3 indexed citations
19.
Hersh, E. & G P Bodey. (1970). Leukocytic Mechanisms in Inflammation. Annual Review of Medicine. 21(1). 105–132. 29 indexed citations
20.
Butler, William T., Roger D. Rossen, E. Hersh, et al.. (1970). Prevention of rapid immune elimination of antilymphocytic globulin in transplant patients. Transplantation. 10(1). 110–110. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J J Gibbons Breakdown of academic impact, for papers by Thomas Coyle Breakdown of academic impact, for papers by Yuya Nagai Breakdown of academic impact, for papers by Marina Panozzo Breakdown of academic impact, for papers by Martina Anzaghe Breakdown of academic impact, for papers by Eiji Shinya Breakdown of academic impact, for papers by Martin Salden Breakdown of academic impact, for papers by María Fernanda Pascutti Breakdown of academic impact, for papers by Vicky M.-H. Sung Breakdown of academic impact, for papers by Gianna Fiorucci
Rankless by CCL
2026